Accessibility Menu
Lb Pharmaceuticals logo

Lb Pharmaceuticals(NASDAQ) LBRX

Current Price$34.57
Market Cap$1.03BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2025)+107%
5 YearN/A
1 YearN/A
1 Month+20%
Lb Pharmaceuticals last closing stock price
MetricPriceDate
Last closeUSD 35.842026-07-22
Lb Pharmaceuticals stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+11.44%USD 32.162026-07-15
1 month+19.99%USD 29.872026-06-22
3 month+16.46%USD 30.782026-04-23
Year to date+61.01%USD 22.262025-12-31
Since inception+107.17%USD 17.302025-09-11

Lb Pharmaceuticals Financials at a Glance

Market Cap

$1.03BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$0.00

Net Income (TTM)

-$39.17M

EPS (TTM)

-$1.49

P/E Ratio

-24.12

Dividend

$0.00

Beta (Volatility)

0.88 (Low)

Price

$34.57

Volume

6,235

Open

$35.64

Previous Close

$35.84

Daily Range

$34.33 - $36.24

52-Week Range

$13.36 - $36.60

Estimated Earnings Date

Aug 11, 2026

LBRX News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Lb Pharmaceuticals

LB Pharmaceuticals makes drugs for severe mental health conditions. Its main product treats symptoms like hallucinations and mood swings. These medicines help patients live more stable, independent lives.

Pills and Pipelines

  • LB-102 (Schizophrenia): Oral drug in Phase 3 trials for managing acute symptoms; targets hallucinations, social withdrawal, and cognitive problems.
  • LB-102 (Bipolar Depression): Phase 2 treatment focused on controlling depressive states in patients with bipolar 1 disorder.
  • Long-Acting Injectable: Injectable version of the lead drug designed to improve patient adherence to treatment schedules.
  • Major Depressive Disorder: Planned adjunctive therapy to be added to existing medications for patients who do not respond to standard treatments.

Recent Growth Steps

  • Announced positive Phase 2 clinical data for acute schizophrenia in January 2025.
  • Initiated a Phase 3 trial for schizophrenia in March 2026.
  • Started a Phase 2 trial for bipolar 1 depression in January 2026.
  • Planned the start of a Phase 2 trial for major depressive disorder for early 2027.

What Makes LB-102 Different?

The company uses a chemical change called methylation to help its lead drug enter the brain more easily. This design allows for lower doses and once-daily use compared to older versions of the medication.

A Look at the Numbers

  • Revenue was $0 in Q4 2025 as the company has no products for sale.
  • Operating income reached -$13.9 million for the quarter ended December 31, 2025.
  • Net income was -$11.5 million in Q4 2025.
  • Free cash flow hit -$18.1 million in Q4 2025.

Bottom Line

LB Pharmaceuticals is moving from research to late-stage clinical testing of its lead candidate. Its success depends on trial results and regulatory approval for its psychiatric therapies.

AI Generated • May 2, 2026

Industry

Pharmaceuticals

Sector

Health Care

Employees

27

CEO

Heather D. Turner

Website

www.lbpharma.us

Headquarters

New York, NY 10119, US

LBRX Financials

Key Financial Metrics (TTM)

Gross Margin

0.00%

Operating Margin

0.00%

Net Income Margin

0.00%

Return on Equity

-17.68%

Return on Capital

-9.97%

Return on Assets

-9.95%

Earnings Yield

-4.15%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$1.03BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

28.68M

Volume

6.24K

Avg. Volume

239.38K

Financials (TTM)

Gross Profit

-$82.00K

Operating Income

-$46.86M

EBITDA

-$39.05M

Operating Cash Flow

-$50.37M

Capital Expenditure

-$63.00K

Free Cash Flow

-$50.43M

Cash & ST Invst.

$365.64M

Total Debt

$3.47M

Lb Pharmaceuticals Performance Analysis

Lb Pharmaceuticals annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 0N/A
20232023-12-31USD 0N/A
20242024-12-31USD 0N/A
20252025-12-31USD 0N/A
Lb Pharmaceuticals sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-30N/A
Q32025-09-30N/A
Q42025-12-31N/A
Q12026-03-31N/A
Lb Pharmaceuticals annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD -0.64N/A
20232023-12-31USD -0.28-56.3%
20242024-12-31USD -2.81905.6%
20252025-12-31USD -1.00-64.6%
Lb Pharmaceuticals sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-30N/A
Q32025-09-3099.3%
Q42025-12-31-221.4%
Q12026-03-31-48.9%

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q1 2026YOY CHG

Revenue

$0.00

N/A

Gross Profit

-$82.00K

N/A

Gross Margin

0.00%

N/A

Market Cap

$1.03BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$38.07M

N/A

Employees

27

N/A

Net Income

-$19.05M

-274.5%

EBITDA

-$18.97M

-263.7%

Quarterly Fundamentals

Name
Q1 2026YOY CHG

Total Cash

$365.64M

+2470.4%

Total Debt

$3.47M

-7.7%

Accounts Receivable

$0.00

N/A

Inventory

$0.00

N/A

Long Term Debt

$2.74M

-9.6%

Short Term Debt

$730.00K

+0.0%

Return on Assets

-9.95%

N/A

Return on Invested Capital

-12.25%

N/A

Free Cash Flow

-$23.32M

-186.2%

Operating Cash Flow

-$23.29M

-186.5%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
DSGNDesign Therapeutics, Inc.
$11.75-0.29%
SLDBSolid Biosciences Inc.
$8.10-0.06%
ANNXAnnexon, Inc.
$5.21-0.48%
AURAAura Biosciences, Inc.
$7.13+1.64%

Trending Stocks

Symbol / CompanyPricePrice Chg
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares
$7.88-0.28%
SQQQProShares Trust - ProShares UltraPro Short Qqq
$43.16+0.05%
HBANHuntington Bancshares
$17.38-0.05%
MUUDirexion Shares ETF Trust - Direxion Daily Mu Bull 2x Shares
$37.03+0.08%

Questions About LBRX

What is the current price of Lb Pharmaceuticals?

Lb Pharmaceuticals is trading at $34.57 per share.

What is the 52-week range for Lb Pharmaceuticals?

Over the past 52 weeks, Lb Pharmaceuticals has traded between $13.36 and $36.60.

How much debt does Lb Pharmaceuticals have?

As of the most recent reporting period, Lb Pharmaceuticals reported total debt of $3.47M.

How much cash does Lb Pharmaceuticals have on hand?

Lb Pharmaceuticals reported $320.68M in cash and cash equivalents in its most recent financial results.

What is Lb Pharmaceuticals’s dividend yield?

Lb Pharmaceuticals does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services